NanoSyrinx
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy.
NanoSyrinx has raised €19M across 2 funding rounds from 10 investors, most recently a round in Sep 2024. Based in Coventry, UK; active in Healthtech. Data as of 28 Oct 2026.
Coventry, UKwww.nanosyrinx.com ↗
Total raised
€19M
€19,083,926
Funding rounds
2
Investors
10
distinct backers
Active since
2021-07
latest 2024-09
Funding by year
EUR raised per yearNanoSyrinx — funding by year — interactive chart.
Data table
| NanoSyrinx — funding by year | |
|---|---|
| 2021 | €7.2M |
| 2024 | €12M |
Signals
High confidenceRaise-next likelihood24
base rate 30% for Other
- ▼ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ 5y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-09-10 | Other | €12M | BGF,Eli Lilly,IQ Capital,M Ventures,Meltwind,Octopus Ventures | View deal → |
| 2021-07-19 | Seed | €7.2M | BioCity,IQ Capital,Jonathan Milner,M Ventures,Octopus Ventures,UK Innovation & Science Seed Fund | View deal → |